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ABSTRACT
Background. The involvement of bacterial translocation 
in the pathogenesis of type 2 diabetes mellitus (T2DM) 
has been highlighted in recent years. The objective of 
the current study was to evaluate the potential impact 
of lipopolysaccaride-binding protein (LBP) and DNA 
translocation on glycemic control and progression to 
diabetic kidney disease in T2DM patients.
Material and methods. A total of 30 T2DM patients as 
well as 30 controls were included in a cross-sectional 
observational study. Plasma LBP levels were deter-
mined using an enzyme linked immunoassay. DNA 
translocation was assessed using polymerase chain 
reaction targeting 16SrNA gene. 
Results. Plasma levels of LBP were significantly elevated 
in T2DM patients than in controls (p = 0.02). LBP level 
was significantly and positively correlated with fasting 
glucose level, glycated hemoglobin, C-reactive protein, 
albumin-creatinine ratio and negatively correlated 
with glomerular filtration rate. Receiver operating 
curve revealed that LBP with a cut off of 15.17 µg/mL 
succeeded to predict both glycemic control and dia-
betic kidney disease in T2DM patients. The bacterial 
16SrRNA was detected in almost all blood samples of 
T2DM patients (28/30) and in about half (16/30) of the 
control group (p < 0.001). 
Conclusion. Translocation products could trigger diabe-
tes related complications. Future interventional work 
should target these products to reverse their effects. 
(Clin Diabetol 2019; 8, 4: 195–204)
Key words: type 2 diabetes mellitus, diabetic kidney 
disease, lipopolysaccharide binding protein, DNA 
translocation, bacterial translocation
Introduction 
Type 2 diabetes mellitus (T2DM) is a metabolic dis-
order characterized by hyperglycemia, insulin resistance 
and systemic inflammation [1]. Several life-threatening 
complications are associated with T2DM [1]. Therefore, 
understanding the possible mechanisms involved in the 
pathogenesis of T2DM or its complications is of great 
value to prevent its progression. Recent data suggests a 
role of the gut microbiota in the induction of systemic 
inflammation and consequently the regulation of glu-
cose metabolism [2].
Changes in gut bacteria, combined with increased 
intestinal permeability, stimulate bacterial translocation 
through the gut barrier; a previously unconsidered 
source of inflammation. Markers of bacterial trans-
location include bacterial 16srRNA DNA and lipo- 
polysaccharide (LPS) [3]. Upon translocation into the 
bloodstream, LPS induces metabolic endotoxemia 
followed by low-grade systemic inflammation involv-
ing the release of pro-inflammatory cytokines, such 
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as tumor necrosis factor (TNF), interleukin 1 (IL 1), and 
interleukin 6 (IL 6) [4].
LPS binds to LPS-binding protein (LBP), a plasma 
protein synthesized mainly by the liver, which facilitates 
the interaction between LPS and cellular targets. Bind-
ing of LPS to LBP is the first step in an inflammatory 
cascade [5]. 
Since LPS has a short half-life and its measurement in 
biologic fluids has several limitations, together with the 
relatively slow rise of LBP, which could serve to monitor 
the interaction between LPS and innate immune cells, 
LBP level has been suggested as a good clinical marker 
of effective metabolic endotoxemia [6, 7]. Several stud-
ies have demonstrated that increased circulating levels 
of LBP were associated with obesity, and T2DM [8–11].
An inflammatory component has been related to 
the complications of diabetes and diabetic kidney dis-
ease. The involvement of inflammatory process draws 
the attention of researchers to use immunosuppres-
sants to prevent the development of albuminuria and 
kidney disease [11].
In this context, the influence of DNA translocation 
or LBP concentrations on glycemic control, and on the 
progression of diabetic kidney disease in T2DM was 
evaluated in the present study. 
Subjects and methods
A total of 30 T2DM patients, recruited from the 
Outpatient Clinic of Alexandria Main University Hospi-
tal, Egypt were included in this cross-sectional observa-
tional study. Subjects were diagnosed as having T2DM 
according to the report of the Expert Committee for 
the Diagnosis and Classification of Diabetes Mellitus 
[12]. Another 30 non-diabetic healthy subjects served 
as a control group. Patients with type 1 DM, other 
metabolic diseases, liver or cardiac disease, portal hy-
pertension, infectious diseases, psychiatric problems, 
and hematological or malignant disease were excluded 
from the study. Patients on anti-inflammatory drugs as 
glucocorticoids or those on antibiotic therapy during 
the last 3 months were also excluded. None of the 
control subjects were under medication or had evidence 
of systemic or metabolic disease. An informed written 
consent was taken from each subject before inclusion in 
the study. The study was approved by the Ethics Com-
mittee of Alexandria Main University Hospital, Egypt.
All subjects were subjected to the following:
History taking and full clinical examination
Demographic data as age and sex were recorded. 
Body weight and height were measured using standard-
ized methods. Body mass index (BMI) was calculated. 
Blood pressure was recorded.
Laboratory routine analyses
Sample collection
Venous blood samples (5 mL from each patient) 
were collected. Sampling was done in the morning 
after an overnight fast. Fresh serum and plasma sam-
ples were used for chemical and hematological tests, 
while aliquots from frozen whole blood samples and 
plasma samples were stored at –80°C for PCR and LBP 
testing respectively.
Chemical and hematological analyses
Routine chemical and hematological tests were 
performed using automated analyzers. Insulin resist-
ance was calculated on the basis of the homeostasis 
model assessment of IR (HOMA-IR), using the following 
formula: [HOMA-IR] = (fasting insulin (mU/L) × fast-
ing glucose (mmol/L)/22.5) [13]. Glomerular filtration 
rate (GFR) was estimated using CKD-EPI equation [14]. 
Moderately increased albuminuria was defined as two 
positive urine samples with urinary albumin-creatinine 
ratio (ACR) of 30–300 in the past 3 months [14].
Measurement of plasma LBP
Plasma level of LBP was determined by a com-
mercially available double antibody sandwich enzyme 
linked immunosorbent assay (Assay kit Co., Ltd, USA) 
according to the manufacturer’s instructions. 
Detection of bacterial DNA by polymerase  
chain reaction (PCR)
Detection of bacterial DNA in patients’ blood was 
performed using PCR targeting 16SrRNA gene pres-
ent in all bacteria, b-galactosidase gene found in most 
E. coli, and glutamine synthase gene of Bacteroides 
fragilis (B. fragilis), using specific primers as previously 
described [15]. 
DNA extraction from whole blood samples was 
done using GENEJET whole blood DNA extraction kit 
(ThermoFisher SCIENTIFIC) according to the manufac-
turer’s instructions.
Each PCR reaction consisted of 12.5 µL master mix 
(DreamTaq Green PCR master mix (2 ×), 25 picomoles/µL 
of the primer to be used, 5 µL of extracted DNA and 
sterile deionized water to a final volume of 25 µL. PCR 
amplification reaction was carried out using Applied 
Biosystems 2720, thermal cycler in the following con-
ditions: an initial denaturation step at 95°C for 3 min, 
followed by 60°C for 45 sec, and 72°C for 10 min. This 
was followed by 35 cycles of denaturation at 95°C for 
45 sec, annealing at 60°C for 45 sec, extension at 72°C 
for 1 min, and finally an extension step at 72°C for 10 
min. PCR products were electrophoresed on 1% aga-
rose gels (Bioline, UK) stained with ethidium bromide. 
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A 100 bp DNA ladder (Thermo Fisher SCIENTIFIC) was 
used as a marker.
Statistical analysis
Data were analyzed using IBM SPSS software pack-
age version 20.0. Qualitative data were described using 
number and percent. Quantitative data were described 
using range, arithmetic mean, standard deviation 
and median. Appropriate tests were used to compare 
quantitative and qualitative variables between the two 
studied groups. For data correlation Pearson correlation 
coefficients was used. Receiver operating characteris-
tics (ROC) curve analysis was done to determine the 
LBP cutoff point, which has the highest sensitivity and 
specificity. Significance of the obtained results was 
judged at the 5% level. 
Results 
Study population characteristics
The mean age of T2DM subjects was 53.3 ± 6.95 
years. Twenty-two (73.3%) subjects were females and 
eight (26.7%) subjects were males. The mean age of 
the control group was 47.17 ± 11.0 with 23 males 
(76.7%) and 7 females (23.3%). 
Comparison of clinical and laboratory parame-
ters between diabetics and control group
The clinical and laboratory data of the study sub-
jects are reported in Table 1. 
Results of bacterial translocation markers
When investigating bacterial translocation markers, 
it was revealed that the mean LBP plasma level was 
significantly higher in patients with T2DM compared 
with control group (19.25 ± 12.69 µg/mL and 13.49 ± 
2.25 µg/mL respectively) (p = 0.02) as shown in Table 1.
Regarding 16SrRNA DNA, it was found that most 
of the T2DM cases (28/30; 93.3%) had circulating DNA 
compared to about half of the control group (16/30; 
53.3%), this difference was statistically significant 
(c2 = 12.273*, p ≤ 0.001) (Figure 1).
None of the T2DM cases or the control group was 
positive for glutamine synthase gene of Bacteroides 
fragilis, or b-galactosidase gene of E. coli.
To exclude the effect of obesity, diabetic cases 
were further subdivided according to BMI into obese 
(n = 26) and non-obese (n = 4) group. Comparison of 
LBP plasma level and the presence of circulating DNA 
between the two groups demonstrated that the mean 
LBP level of the obese group was 20.36 ± 13.16 µg/mL 
compared to 12.07 ± 6.02 µg/mL in the non-obese 
group, with no statistically significant difference be-
tween the two groups (ZU = –1.403, p = 0.161). Most 
of the obese (92.3%) and all non-obese (100%) had 
positive 16SrRNA DNA with no statistically significant 
difference between the two groups. (c2 = 0.33, p = 
= 1.0). This finding supports the idea that obesity was 
not a major cause of the differences.
Correlation of LBP with various clinical  
and laboratory parameters
Circulating plasma LBP level was significantly and 
positively correlated with BMI (r = 0.342, p = 0.008), 
waist circumference (r = 0.361, p = 0.005), total 
cholesterol level (r = 0.470, p < 0.001), LDL-C (r = 
=  0.518, p < 0.001), fasting glucose level (r = 0.343, 
p = 0.007), HbA1c (r = 0.269, p < 0.037), CRP (r = 0.585, 
p < 0.001), and ACR (r = 0.320, p < 0.013). On the 
other hand, there was a statistically significant nega-
tive correlation between LBP level and GFR (r = –0.289, 
p = 0.025) (Table 2).
Table 3 shows that the model is highly significant 
with p value < 0.001, 45% of the variability in LBP 
level could be explained by this model (R2 = 0.451). 
CRP was the only variable which is independently and 
positively associated with plasma LBP levels (p = 0.001). 
The higher the CRP level the higher the LBP; one mg/L 
increase in CRP will increase the LBP by 0.215 µg/mL 
holding the other predictors constant (Table 3).
The diagnostic value of LBP for prediction of 
glycemic control, and diabetic kidney disease
ROC curves were plotted to evaluate the diagnostic 
value, in terms of area under curve (AUC), of LBP in 
prediction of glycemic control as well as diabetic kidney 
disease; the proposed threshold value (cutoff point) of 
LBP was ≥ 15.17 µg/mL (Figure 2A–D).
Relation of DNA translocation and various  
clinical and laboratory parameters in diabetics 
and control subjects
Comparison of different study parameters between 
subjects with positive and negative circulating 16SrRNA 
DNA (whether diabetics or controls) was performed. 
The mean BMI values in diabetic patients who had cir-
culating DNA (34.68 ± 4.48 kg/m2), was significantly 
higher than among controls (29.69 ± 3.27 kg/m2) 
(p ≤ 0.001). Similarly, the waist circumference’s mean 
in diabetic patients who had circulating DNA (116.43 ± 
± 5.36 cm) was significantly higher than in the other 
groups (p = 0.003).
Regarding the lipid profile, it was found that the 
mean values of triglycerides (181.32 ± 73.69 mg/dL), 
cholesterol (216.04 ± 24.92 mg/dL), LDL-C levels 
(137.14 ± 19.6 mg/dL), in diabetic patients with circu-
lating DNA, were significantly higher than in the other 
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Table 1. Comparison between the two studied groups according to clinical and laboratory measures
Clinical and laboratory 
parameters
T2DM cases 
(n = 30)
Controls 
(n = 30)
Test of significance p value
BMI [kg/m2]
   Min.–max.
   Mean ± SD
   Median
26.29–42.96
34.79 ± 4.36
35.15
24.91–36.15
29.37 ± 3.03
28.05
ZU = –4.459* < 0.001*
Waist circumference [cm]
   Min.–max.
   Mean ± SD
   Median
109–127
116.0 ± 5.43
115.0
100–125
110.77 ± 5.79
109.5
t = 3.611* 0.001*
Mean blood pressure [mm Hg]
   Min.–max.
   Mean ± SD
   Median
80–113.3
101.27 ± 7.71
103.3
86.7–106.7
98.83 ± 7.29
101.7
t = 1.261 0.212
TG [mg/dL]
   Min.–max.
   Mean ± SD
   Median
90–371
180.33 ± 71.2
174.0
98–150
126.03 ± 14.59
124.0
ZU = –3.466* 0.001*
Total cholesterol [mg/dL]
   Min.–max.
   Mean ± SD
   Median
176–272
216.4 ± 24.52
217.0
145–210
173.63 ± 15.27
170.0
t = 8.11* < 0.001*
HDL-C [mg/dL]
   Min.–max.
   Mean ± SD
   Median
30–67
43.3 ± 8.69
42.0
41–60
49.4 ± 5.59
50.0
ZU = –3.47* 0.001*
LDL-C [mg/dL]
   Min.–max.
   Mean ± SD
   Median
104.4–188.8
136.74 ± 20.24
133.8
66–131
99.0 ± 15.75
99.5
t = –3.234* 0.002*
Fasting glucose [mg/dL]
   Min.–max.
   Mean ± SD
   Median
78–571
236.87 ± 114.03
215.5
80–111
93.2 ± 6.98
93.0
ZU = –5.836* < 0.001*
Fasting insulin [mLU/mL]
   Min.–max.
   Mean ± SD
   Median
5.21–52.2
14.7 ± 8.77
12.0
5.2–15.3
10.49 ± 2.88
11.1
ZU = –1.738 0.082
HOMA-IR
   Min.–max.
   Mean ± SD
   Median
1.7–23.6
8.04 ± 4.58
7.65
1.1–3.8
2.39 ± 0.63
2.4
ZU= –5.829* < 0.001*
HbA1c (%)
   Min.–max.
   Mean ± SD
   Median
6.2–13.3
9.82 ± 2.25
10.0
4.9–6.0
5.33 ± 0.28
5.3
ZU = –6.663* < 0.001*
Hb [gm/dL]
   Min.–max.
   Mean ± SD
   Median
13–17
14.76 ± 1.09
14.7
13–17
15.1 ± 0.99
15.0
t = –1.267 0.210
Æ
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Table 1. (cont.). Comparison between the two studied groups according to clinical and laboratory measures
Clinical and laboratory 
parameters
T2DM cases 
(n = 30)
Controls 
(n = 30)
Test of significance p value
WBCs (cells/cmm)
   Min.–max.
   Mean ± SD
   Median
6.3–12.26
8.76 ± 1.73
8.35
4.24–18.9
6.79 ± 2.73
6.29
ZU = –4.288* < 0.001*
Platelets (cells/cmm)
   Min.–max.
   Mean ± SD
   Median
159–400
261.5 ± 57.29
252.5
184–369
259.1 ± 47.66
248.0
t = 0.176 0.861
ALT [U/L]
   Min.–max.
   Mean ± SD
   Median
11–44
19.5 ± 7.56
19.5
11–29
19.1 ± 4.39
20.0
ZU = –0.423 0.672
AST (U/L)
   Min.–max.
   Mean ± SD
   Median
12–57
19.33 ± 10.13
15.5
11–28
19.07 ± 4.40
19.0
ZU = –1.312 0.189
Serum albumin [g/dL]
   Min.–max.
   Mean ± SD
   Median
2.9–4.5
3.47 ± 0.45
3.45
3.5–4.9
4.17 ± 0.34
4.1
t = –6.748 < 0.001*
Urea [mg/dL]
   Min.–max.
   Mean ± SD
   Median
50–200
111.73 ± 43.25
100.0
12–45
22.3 ± 9.11
19.5
ZU = –6.657* < 0.001*
Creatinine [mg/dL]
   Min.–max.
   Mean ± SD
   Median
0.9–3.0
1.68 ± 0.52
1.6
0.4–1.0
0.74 ± 0.18
0.7
ZU = –6.459* < 0.001*
GFR [mL/min/1.73 m2]
   Min.–max.
   Mean ± SD
   Median
27.41–131.0
62.64 ± 22.98
60.7
92.22–242.01
156.68 ± 42.54
155.9
ZU = –6.416* < 0.001*
ACR [mcg/mg]
   Min.–max.
   Mean ± SD
   Median
22.8–8000.0
1506.4 ± 1909.7
835.0
10.0–30.0
21.37 ± 5.48
22.5
ZU = –6.436* < 0.001*
ESR [mm/hr]
   Min.–max.
   Mean ± SD
   Median
20–132
60.23 ± 32.35
69.0
10–23
15.2 ± 3.93
14.5
ZU = –6.386* < 0.001*
CRP [mg/L]
   Min.–max.
   Mean ± SD
   Median
4–90
31.07 ± 23.07
21.0
3–16
10.07 ± 3.76
11.0
ZU= –4.557* < 0.001*
LBP [µg/mL]
   Min.–max.
   Mean ± SD
   Median
4.14–63.04
19.25 ± 12.69
16.44
11.01–17.9
13.49 ± 2.25
12.62
ZU = –2.323* 0.02*
t — calculated value for Student t-test; ZU — calculated value for Mann Whitney non-parametric test; * — statistically significant at p ≤ 0.05; BMI — body 
mass index; TG — triglycerides; HDL-C — high-density lipoprotein; LDL-C — low-density lipoprotein; HOMA-IR — homeostatic model assessment for insulin 
resistance; HbA1c — glycosylated hemoglobin; CRP — C-reactive protein; Hb — hemoglobin; ALT — alanine aminotransferase; AST — aspartate aminotrans-
ferase; GFR — glomerular filtration rate; ACR — albumin/creatinine ratio; ESR — erythrocyte sedimentation rate; CRP — C-reactive protein;  
LBP — lipopolysaccharide binding protein
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groups (p = 0.007; p ≤ 0.001; p ≤ 0.001 respectively). 
Moreover, HDL-C mean (42.32 ± 7.67 mg/dL) was sig-
nificantly lower in diabetics who had circulating DNA 
(p = 0.001).
In addition, diabetic patients with positive circulat-
ing DNA had significantly higher mean levels of fasting 
blood glucose (234.43 ± 117.76 mg/dL), HOMA-IR 
score (8.04 ± 4.72), HbA1c (9.69 ± 2.27%) than 
diabetics or controls with negative DNA translocation 
(p ≤ 0.001, p = 0.008, p ≤ 0.001 respectively).
The mean white blood cells count was the highest 
in diabetic patients with DNA translocation, while the 
mean serum albumin was the least in the same group. 
These differences were statistically significant (p ≤ 0.001). 
On the other hand, hemoglobin level, platelets count, 
ALT, and AST did not differ significantly between 
different groups.
The mean levels of urea (1.68 ± 0.54 mg/dL), cre-
atinine (112.14 ± 44.72 mg/dL), albumin/creatinine 
ratio (1556.88 ± 1967.5 µg/mg) were significantly 
higher in diabetic patients with circulating DNA when 
compared to control subjects with circulating DNA, or 
subjects who had no circulating DNA whether diabet-
ics or non-diabetics (p ≤ 0.001). Also, the mean GFR 
in diabetic patients who had circulating DNA was 
significantly lower than in subjects who had no DNA 
whether diabetics or not (p ≤ 0.001).
Comparing the inflammatory markers between 
the four groups, revealed that the ESR (59.32 ± 33.32 
mm/hr) as well as the CRP (31.93 ± 23.66 mg/L) mean 
levels in diabetics with circulating DNA were signifi-
cantly higher than in the subjects with negative DNA 
translocation (p ≤ 0.001).
Although, the mean level of LBP was higher in 
diabetic patients (19.41 ± 13.14 µg/mL) who had circu-
lating DNA compared to controls (14.03 ± 2.19 µg/mL) 
with circulating DNA, or diabetics and controls who 
had no DNA (17.09 ± 1.36 µg/mL, 12.87 ± 2.24 µg/mL 
respectively), these differences were not statistically 
significant (p = 0.067).
Discussion 
To our knowledge, this study is the first to examine 
the effect of endotoxemia and bacterial translocations 
on glycemic control or progression of diabetic kidney 
disease in an Egyptian population having T2DM.
The results of the anthropometric and laboratory 
parameters of the diabetic patients in the present study 
were similar to data obtained from previous studies 
[18–20]. Although several studies have investigated the 
association of LBP and other translocation markers with 
T2DM [8–11], few studies have focused on the associa-
tion of LBP or DNA translocation and the progression 
of diabetes in type 2 diabetic patients. 
Figure 1. Agarose gel stained with ethidium bromide. A band of 798 bp corresponds to bacterial broad range16SrRNA gene, a 
band of 762 bp corresponds to E. coli b-galactosidase gene (BG), a band of 581 bp corresponds to Bacteroides fragilis glutamine 
synthase (GS) gene, and a band of 268 bp corresponds to internal control b-globin gene. Lane 1: blood sample spiked with E. 
coli ATCC 25922; 16SrRNA gene positive control (798 bp). Lane 2: blood sample spiked with E. coli ATCC 25922; BG gene positive 
control (762 bp). Lane 3: blood sample spiked with Bacteroides fragilis ATCC 25285; glutamine synthase gene positive control 
(581 bp). Lane 4, 5, 6: Positive Blood sample (positive 16SrRNA gene in lane 4, negative BG gene in lane 5, negative GS gene 
in lane 6). Lane 7, 9, 10: Positive blood sample (positive 16SrRNA gene in lane 7, negative BG gene in lane 9, negative GS gene 
in lane 10). Lane 11, 12, 13: Negative blood sample for the three genes. Lane 14, 15: Negative controls. Lane 8: molecular size 
DNA marker (100–1000 bp)
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observed between serum LBP levels and the incidence of 
T2DM in the 5-year follow-up. They concluded that LBP 
on its own might not improve diabetes prediction [21]. 
In the current work, LBP was statistically sig-
nificantly positively correlated with BMI and waist 
circumference in diabetic patients. It was also positively 
correlated with blood sugar level, HbA1c, total choles-
terol, LDL-C, ACR and CRP. However, LBP was negatively 
correlated with GFR. Similarly, Kim et al., assessed LBP 
as a biomarker of obesity-related insulin resistance in 
adolescents, the results of their study showed LBP levels 
were significantly and positively associated with BMI 
[22]. Furthermore, circulating plasma LBP levels were 
significantly and positively associated with BMI, systolic 
blood pressure, aspartate aminotransferase, alanine 
aminotransferase, total cholesterol, LDL-C, fasting glu-
cose and insulin, and insulin resistance in the study of 
Moreno-Navarrete et al. [9]. Serum LBP levels were also 
positively correlated with the parameters of obesity, 
insulin resistance, and inflammation in diabetic subjects 
as mentioned in a previous Japanese study [23]. In a 
prospective observational study involving 49 obese 
subjects undergoing bariatric surgery and 17 controls, 
plasma LPS was positively correlated with cardiometa-
bolic risk factors, including triglycerides, systolic blood 
pressure, and BMI and was negatively correlated with 
HDL cholesterol [24]. Kim et al., found that plasma LBP 
levels were significantly and positively correlated with 
liver enzyme levels, a marker of liver damage and liver 
involvement in systemic inflammatory disease [22]. This 
observation was not encountered in our study where 
the LBP levels were not correlated with liver enzymes. 
Tabela 2. Correlations of plasma LBP levels with various 
parameters
Studied variables LBP level
r p value
BMI 0.342* 0.008*
Waist circumference 0.361* 0.005*
Mean blood pressure 0.117 0.375
Triglycerides 0.182 0.164
Total cholesterol 0.470* < 0.001*
HDL-C –0.229 0.078
LDL-C 0.518* < 0.001*
Fasting blood glucose 0.343* 0.007*
Fasting insulin –0.166 0.204
HOMA-IR 0.088 0.503
HbA1c 0.269
* 0.037*
Hb –0.089 0.498
WBCs count 0.056 0.672
Platelets count –0.237 0.068
ALT –0.019 0.887
AST –0.065 0.623
Serum albumin –0.135 0.304
Urea 0.139 0.289
Creatinine 0.211 0.105
GFR –0.289* 0.025*
ACR 0.320* 0.013*
ESR 0.206 0.114
CRP 0.585* < 0.001*
r — Spearman correlation coefficient; *— statistically significant at  
p ≤ 0.05. BMI — body mass index; HDL-C — high density lipoprotein; 
LDL-C — low density lipoprotein; HOMA-IR — homeostatic model 
assessment of insulin resistance; HbA1c — glycosylated hemoglobin; 
Hb — hemoglobin; ALT — alanine aminotransferase; AST — asparta-
te aminotransferase; GFR — glomerular filtration rate; ACR — albu-
min/creatinine ratio; ESR — erythrocyte sedimentation rate;  
CRP — C-reactive protein
Tabela 3. Multiple linear regression analysis of factors 
affecting LBP level 
Studied variables LBP level
B t p
BMI 0.249 0.817 0.418
Waist circumference 0.032 0.152 0.879
Cholesterol 0.011 0.103 0.918
LDL-C 0.105 0.842 0.404
FBG –0.002 –0.124 0.902
HbA1c –0.778 –1.088 0.282
GFR –0.005 –0.174 0.863
CRP 0.215 3.364 0.001*
ACR 0.0 –0.336 0.738
F (P) 4.558* (< 0.001*)
R2 0.451
B — regression coefficient; t, p — calculated and p-value of t-test; F (P) 
— calculated and p-value of ANOVA test; * — statistically significant at 
p ≤ 0.05
In the present study, the mean LBP level of the cases 
was significantly higher than that of the control group 
(p = 0.02). This was in agreement with a previous study, 
which examined the associations between intestinal 
permeability and T2DM, LBP was significantly higher 
in type 2 diabetic patients in comparison with normal 
individuals [19]. Similarly, Gubern et al., verified higher 
LBP concentration in T2DM patients and subjects with 
impaired glucose tolerance compared with non-diabetic 
subjects [20]. Also, Moreno-Navarrete et al., found that 
type 2 diabetic patients have higher levels of LBP than 
controls [9]. On the other hand, Zhou et al., conducted a 
5-year nested case-control study on 3510 individuals from 
the Chinese population. Based on the results of their study, 
there was no significant difference in LBP levels at baseline 
between T2DM subjects and controls when matched for 
age, gender, and BMI. In addition, no association was 
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Our results demonstrated that CRP was the only 
variable which is independently and positively associ-
ated with plasma LBP levels (p = 0.001). The higher 
the CRP level the higher the LBP concentrations. In-
terestingly, Sun et al., observed a stronger correlation 
between LBP and inflammatory markers after adjust-
ment for BMI. Moreover, adjusting for hs-CRP and IL-6 
almost eliminated the associations of LBP with meta-
bolic syndrome and most of its traits. The explaining 
mechanism is that LBP triggered an immune response 
involving formation of interleukins and upregulation 
of CRP synthesis in the liver [10].
After analyzing ROC curves in the current study, 
using LBP with a cut off of 15.17 µg/mL succeeded 
to predict both glycemic control and diabetic kidney 
disease in T2DM patients. This finding could help to 
predict complications in T2DM patients in our Egyptian 
population.
Amar et al., reported previously that bacterial 
16S rRNA gene blood concentration could predict the 
onset of diabetes, reporting for the first time the clinical 
importance of bacterial translocation in the develop-
ment of T2DM [25]. 16SrRNA is a highly conserved 
region of bacterial DNA, found in all bacteria; thus by 
its detection by PCR, all translocated bacteria could be 
theoretically detected [26]. Ortiz et al., studied DNA 
translocation in a group of morbidly obese patients 
candidate for bariatric surgery, they found that inflam-
matory markers, endotoxin levels, and insulin resistance 
remained high in patients with bacterial DNA despite 
weight reduction and were individually affected by 
the presence or absence of bacterial DNA transloca-
tion. They demonstrated increased serum levels of 
endotoxin in patients with bacterial DNA compared 
to those without DNA. Moreover, they proved that 
DNA fragments correspond to commensal gut flora 
Figure 2A, B. ROC curves for LBP as a predictor of glycemic control in type 2 diabetes mellitus (A. FBG ≥ 126 mg/dL, B. HbA1c 
≥ 6.5). A. Area under the curve (AUC): 0.723, proposed threshold value: ≥ 15.17 µg/mL, sensitivity: 74.1%, specificity: 75.8%, 
positive predictive value (PPV): 71.4%, negative predictive value (NPV): 78.1% (p = 0.003). B. AUC: 0.669, threshold value: 
≥ 15.17, sensitivity: 67.9%, specificity: 71.9 %, PPV: 67.9%, NPV: 71.9% (p = 0.025). C, D. ROC curves for LBP as a predictor of 
diabetic kidney disease (C. ACR ≥ 30 µg/mg, D. GFR ≥ 90 mL/min/1.73 m2). C. AUC: 0.664, proposed threshold value: ≥ 15.17 µg/mL, 
sensitivity: 63.3%, specificity: 70.0%, PPV: 67.9%, NPV: 65.6% (p = 0.029). D. AUC: 0.738, threshold value: ≥ 15.17 µg/mL, sen-
sitivity: 71.4%, specificity: 75.0%, PPV: 71.4%, NPV: 75.0% (p = 0.002)
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and coincide with elevated serum endotoxin levels in 
those patients [27]. Similarly, Sato et al., found that 
gut bacteria were detected in blood at a significantly 
higher rate in diabetic patients than in control subjects, 
and most of these bacteria were Gram-positive anaero-
bic bacteria [17]. The findings of the previous studies 
support our results that bacterial translocation to the 
blood might play important roles in chronic low-grade 
inflammation in T2DM and could explain the negative 
PCR results of glutamine synthase gene of Bacteroides 
fragilis, or b-galactosidase gene of E. coli. 
To further evaluate the role of bacterial transloca-
tion on the glycemic control, A French study dem-
onstrated that translocation of commensal bacteria 
from intestine towards tissue can be reversed with the 
probiotic strain Bifidobacterium Lactis, which proved 
to improve the epithelial cell gut barrier, thus reducing 
bacterial translocation and its consequences on inflam-
mation and insulin sensitivity [28]. 
While some data on translocation markers and 
their relationship to chronic inflammation is available 
for chronic kidney disease patients [29], very little is 
known about this relationship in T2DM patients. The 
study conducted by Nymark et al., showed that high 
serum LPS activity contributes to the development of 
microalbuminuria and diabetic nephropathy in Finnish 
patients with type 1 diabetes [11]. Disturbance of gut 
flora and consequently bacterial translocation and 
increased inflammatory state, lead to progression of 
diabetic nephropathy, which might be attributed to the 
gut-kidney axis in which local renin-angiotensin system 
is possibly involved [30].
Our study has some limitations. Dietary data and 
treatment data (insulin, or antidiabetis) were limited. 
Both could affect gut bacteria and LBP levels as well 
as DNA translocation. Additionally, we only assessed 
plasma LBP and not LPS levels. Moreover, the PCR 
method used in the study simply demonstrates the 
presence of bacterial DNA, does not specify type of 
bacteria, and does not differentiate between dead or 
living microorganisms.
Conclusions 
In conclusion, our study demonstrated that bacte-
rial translocation markers are present at increased levels 
in patients with T2DM, and are positively correlated 
with glycemic control, renal and inflammatory markers. 
They might then trigger diabetes related complications 
as diabetic kidney disease. 
Future research should focus on interventional 
protocols to investigate whether manipulation of gut 
microbiota by dietary interventions or by the adminis-
tration of probiotics could reduce the rate of bacterial 
translocation. This might decrease systemic inflam-
matory response and eventually ameliorate glycemic 
control, and decrease the risk of progression of diabetic 
kidney disease.
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